Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma

Misato Kikuchi, Hideki Nakasone, Yu Akahoshi, Hirofumi Nakano, Tomotaka Ugai, Hidenori Wada, Ryoko Yamasaki, Kana Sakamoto, Koji Kawamura, Yuko Ishihara, Miki Sato, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun Ichi Kimura, Rie Yamazaki, Shinichi Kako, Junya Kanda, Junji Nishida, Naohiro Sekiguchi, Satoshi NotoMichiko Kida, Akira Hangaishi, Kensuke Usuki, Yoshinobu Kanda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.

Original languageEnglish
Pages (from-to)99-105
Number of pages7
JournalJournal of Chemotherapy
Volume27
Issue number2
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Drug Therapy
Febrile Neutropenia
Follicular Lymphoma
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
Neutropenia
Disease-Free Survival
Lymphoma
B-Lymphocytes
Therapeutics
R-CHOP protocol
Survival
Mortality
Incidence

Keywords

  • Diffuse large B-cell lymphoma
  • Elderly patients
  • Neutropenia
  • Non-Hodgkin lymphoma
  • R-CHOP
  • Relative dose intensity
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Kikuchi, M., Nakasone, H., Akahoshi, Y., Nakano, H., Ugai, T., Wada, H., ... Kanda, Y. (2015). Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma. Journal of Chemotherapy, 27(2), 99-105. https://doi.org/10.1179/1973947814Y.0000000219

Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma. / Kikuchi, Misato; Nakasone, Hideki; Akahoshi, Yu; Nakano, Hirofumi; Ugai, Tomotaka; Wada, Hidenori; Yamasaki, Ryoko; Sakamoto, Kana; Kawamura, Koji; Ishihara, Yuko; Sato, Miki; Ashizawa, Masahiro; Terasako-Saito, Kiriko; Kimura, Shun Ichi; Yamazaki, Rie; Kako, Shinichi; Kanda, Junya; Nishida, Junji; Sekiguchi, Naohiro; Noto, Satoshi; Kida, Michiko; Hangaishi, Akira; Usuki, Kensuke; Kanda, Yoshinobu.

In: Journal of Chemotherapy, Vol. 27, No. 2, 01.01.2015, p. 99-105.

Research output: Contribution to journalArticle

Kikuchi, M, Nakasone, H, Akahoshi, Y, Nakano, H, Ugai, T, Wada, H, Yamasaki, R, Sakamoto, K, Kawamura, K, Ishihara, Y, Sato, M, Ashizawa, M, Terasako-Saito, K, Kimura, SI, Yamazaki, R, Kako, S, Kanda, J, Nishida, J, Sekiguchi, N, Noto, S, Kida, M, Hangaishi, A, Usuki, K & Kanda, Y 2015, 'Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma', Journal of Chemotherapy, vol. 27, no. 2, pp. 99-105. https://doi.org/10.1179/1973947814Y.0000000219
Kikuchi, Misato ; Nakasone, Hideki ; Akahoshi, Yu ; Nakano, Hirofumi ; Ugai, Tomotaka ; Wada, Hidenori ; Yamasaki, Ryoko ; Sakamoto, Kana ; Kawamura, Koji ; Ishihara, Yuko ; Sato, Miki ; Ashizawa, Masahiro ; Terasako-Saito, Kiriko ; Kimura, Shun Ichi ; Yamazaki, Rie ; Kako, Shinichi ; Kanda, Junya ; Nishida, Junji ; Sekiguchi, Naohiro ; Noto, Satoshi ; Kida, Michiko ; Hangaishi, Akira ; Usuki, Kensuke ; Kanda, Yoshinobu. / Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma. In: Journal of Chemotherapy. 2015 ; Vol. 27, No. 2. pp. 99-105.
@article{d80ada8d1506430f837f6dfb96118870,
title = "Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma",
abstract = "Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6{\%}, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0{\%}, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2{\%}, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.",
keywords = "Diffuse large B-cell lymphoma, Elderly patients, Neutropenia, Non-Hodgkin lymphoma, R-CHOP, Relative dose intensity, Rituximab",
author = "Misato Kikuchi and Hideki Nakasone and Yu Akahoshi and Hirofumi Nakano and Tomotaka Ugai and Hidenori Wada and Ryoko Yamasaki and Kana Sakamoto and Koji Kawamura and Yuko Ishihara and Miki Sato and Masahiro Ashizawa and Kiriko Terasako-Saito and Kimura, {Shun Ichi} and Rie Yamazaki and Shinichi Kako and Junya Kanda and Junji Nishida and Naohiro Sekiguchi and Satoshi Noto and Michiko Kida and Akira Hangaishi and Kensuke Usuki and Yoshinobu Kanda",
year = "2015",
month = "1",
day = "1",
doi = "10.1179/1973947814Y.0000000219",
language = "English",
volume = "27",
pages = "99--105",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma

AU - Kikuchi, Misato

AU - Nakasone, Hideki

AU - Akahoshi, Yu

AU - Nakano, Hirofumi

AU - Ugai, Tomotaka

AU - Wada, Hidenori

AU - Yamasaki, Ryoko

AU - Sakamoto, Kana

AU - Kawamura, Koji

AU - Ishihara, Yuko

AU - Sato, Miki

AU - Ashizawa, Masahiro

AU - Terasako-Saito, Kiriko

AU - Kimura, Shun Ichi

AU - Yamazaki, Rie

AU - Kako, Shinichi

AU - Kanda, Junya

AU - Nishida, Junji

AU - Sekiguchi, Naohiro

AU - Noto, Satoshi

AU - Kida, Michiko

AU - Hangaishi, Akira

AU - Usuki, Kensuke

AU - Kanda, Yoshinobu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.

AB - Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.

KW - Diffuse large B-cell lymphoma

KW - Elderly patients

KW - Neutropenia

KW - Non-Hodgkin lymphoma

KW - R-CHOP

KW - Relative dose intensity

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84923514218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923514218&partnerID=8YFLogxK

U2 - 10.1179/1973947814Y.0000000219

DO - 10.1179/1973947814Y.0000000219

M3 - Article

C2 - 25314911

AN - SCOPUS:84923514218

VL - 27

SP - 99

EP - 105

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 2

ER -